The standard of care for healing broken bones hasn’t changed in over fifty years. Invasive metal hardware is still routinely used to fixate bones–often with less-than-optimal patient outcomes. RevBio® is a medical device company that has invented TETRANITE®, a regenerative bone adhesive currently in 150 patients across seven FDA approved clinical trials. Our patented “bone glue” is founded upon a comprehensive patent portfolio with global patent protection extending through 2042. Easily injectable into a range of musculoskeletal defects, TETRANITE has demonstrated superior performance over other standard of care options in curing speed and strength, rate of resorption, bone regeneration, and most critically wet-field adhesion. As a novel technology, TETRANITE is anticipated to receive a De Novo classification for several indications which will expedite the path to commercialization by Q3 2027. Bioengineered for a body of applications, the TETRANITE platform will address a total addressable market of over $10 billion in neurosurgical, orthopaedic and dental use cases.